Literature DB >> 24377979

Effect of presentation modality in direct-to-consumer (DTC) prescription drug television advertisements.

Michael S Wogalter1, Eric F Shaver2, Michael J Kalsher3.   

Abstract

Direct-to-consumer (DTC) drug advertising markets medications requiring a physician's script to the general public. In television advertising, risk disclosures (such as side effects and contraindications) may be communicated in either auditory (voice) or visual (text) or both in the commercials. This research examines presentation modality factors affecting the communication of the risk disclosures in DTC prescription drug television commercials. The results showed that risk disclosures presented either visually only or both visually and auditorily increased recall and recognition compared to no presentation. Risk disclosures presented redundantly in both the visual and auditory modalities produced the highest recall and recognition. Visual only produced better performance than auditory only. Simultaneous presentation of non-risk information together with risk disclosures produced lower recall and recognition compared to risk disclosures alone-without concurrent non-risk information. Implications for the design of DTC prescription drug television commercials and other audio-visual presentations of risk information including on the Internet, are discussed.
Copyright © 2013 Elsevier Ltd and The Ergonomics Society. All rights reserved.

Entities:  

Keywords:  Advertisements; Drug commercials; Risk communication

Mesh:

Substances:

Year:  2013        PMID: 24377979     DOI: 10.1016/j.apergo.2013.12.003

Source DB:  PubMed          Journal:  Appl Ergon        ISSN: 0003-6870            Impact factor:   3.661


  6 in total

1.  Attention to and Distraction from Risk Information in Prescription Drug Advertising: An Eye Tracking Study.

Authors:  Helen Sullivan; Vanessa Boudewyns; Amie O'Donoghue; Sandra Marshall; Pamela A Williams
Journal:  J Public Policy Mark       Date:  2017-09-01

2.  Communicating Risk Information in Direct-to-Consumer Prescription Drug Television Ads: A Content Analysis.

Authors:  Helen W Sullivan; Kathryn J Aikin; Jon Poehlman
Journal:  Health Commun       Date:  2017-11-10

3.  An Empirical Examination of the FDAAA-Mandated "Toll-Free Statement" for Consumer Reporting of Side Effects in Direct-to-Consumer Television Advertisements.

Authors:  Kathryn J Aikin; Amie C O'Donoghue; Claudia Squire; Helen W Sullivan; Kevin R Betts
Journal:  J Public Policy Mark       Date:  2016-04-01

4.  Assessing the Inclusion of Foil Items in a Scale to Measure Recognition of Health Messages.

Authors:  Helen W Sullivan; Wen-Hung Chen; Kevin R Betts
Journal:  Commun Methods Meas       Date:  2021-07-03

5.  Taking Repeated Exposure into Account: An Experimental Study of Direct-To-Consumer Prescription Drug Television Ad Effects.

Authors:  Kevin R Betts; Kathryn J Aikin; Bridget J Kelly; Mihaela Johnson; Sarah Parvanta; Brian G Southwell; Nicole Mack; Janice Tzeng; Linda Cameron
Journal:  J Health Commun       Date:  2019-04-29

6.  Serious and actionable risks, plus disclosure: Investigating an alternative approach for presenting risk information in prescription drug television advertisements.

Authors:  Kevin R Betts; Vanessa Boudewyns; Kathryn J Aikin; Claudia Squire; Suzanne Dolina; Jennifer J Hayes; Brian G Southwell
Journal:  Res Social Adm Pharm       Date:  2017-08-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.